CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $8.15B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.49: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.15BUSDvs all stocks (USD)
Trailing P/E
50.16xvs Medical Devices peers
Revenue (TTM)
2.59BUSDvs all stocks (USD)
Profit Margin
6.52%vs Medical Devices peers
Beta
1.08xvs all stocks
52-Week Change
24.61%vs all stocks
Market Capitalization
8.15BUSDvs all stocks (USD)
Enterprise Value
7.73BUSDvs all stocks (USD)
Trailing P/E
50.16xvs Medical Devices peers
Forward P/E
30.96xvs Medical Devices peers
PEG Ratio
-0.0526xvs Medical Devices peers
Price to Sales (TTM)
3.11xvs Medical Devices peers
Price to Book (MRQ)
1.18xvs Medical Devices peers
Enterprise to Revenue
2.98xvs Medical Devices peers
Enterprise to EBITDA
17.37xvs Medical Devices peers
Gross Margin
52.25%vs Medical Devices peers
Profit Margin
6.52%vs Medical Devices peers
Operating Margin
5.76%vs Medical Devices peers
Return on Assets (TTM)
1.79%vs Medical Devices peers
Return on Equity (TTM)
2.50%vs Medical Devices peers
Revenue (TTM)
2.59BUSDvs all stocks (USD)
Revenue per Share (TTM)
95.80USDUpdated Jul 18, 2026Quarterly Revenue Growth
1.10%vs Medical Devices peers
Gross Profit (TTM)
1.35BUSDvs all stocks (USD)
EBITDA (TTM)
478.90MUSDvs all stocks (USD)
Net Income (TTM)
168.80MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.14%vs Medical Devices peers
Operating Cash Flow (TTM)
510.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
229.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
2.58BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.24BUSDFY2025 · Dec 31, 2025Gross Profit
1.34BUSDFY2025 · Dec 31, 2025Operating Income
218.60MUSDvs all stocks (USD)
Pre-tax Income
995.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
235.60MUSDFY2025 · Dec 31, 2025Net Income
759.90MUSDFY2025 · Dec 31, 2025EBIT
1.04BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
480.70MUSDFY2025 · Dec 31, 2025Research & Development
275.60MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
844.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
95.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
49.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
27.87USDFY2025 · Dec 31, 2025EPS (Diluted)
27.85USDFY2025 · Dec 31, 2025Basic Shares Outstanding
27.26MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
27.26MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
759.90MUSDFY2025 · Dec 31, 2025Operating Cash Flow
1.25BUSDFY2025 · Dec 31, 2025Free Cash Flow
1.09BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
532.20MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
759.90MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
165.40MUSDFY2025 · Dec 31, 2025Stock-based Compensation
58.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-3.30MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
19.60MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-100.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
251.40MUSDFY2025 · Dec 31, 2025Capital Expenditures
-157.50MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
-218.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-669.30MUSDFY2025 · Dec 31, 2025Sale of Investments
855.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-189.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-500.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-295.50MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-299.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
26.83MSharesUpdated Jul 18, 2026Float Shares
20.91MSharesUpdated Jul 18, 2026Shares Short
220.00SharesUpdated Jul 18, 2026Short Ratio
0.00daysvs all stocks
Short % of Shares Outstanding
0.00%vs all stocks
% Held by Insiders
16.34%vs all stocks
% Held by Institutions
94.36%vs all stocks
Total Cash (MRQ)
1.56BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
58.47USDUpdated Jul 18, 2026Total Debt (MRQ)
1.38BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2012xvs Medical Devices peers
Current Ratio (MRQ)
3.21xvs Medical Devices peers
Book Value per Share (MRQ)
255.37USDUpdated Jul 18, 2026Total Assets
10.58BUSDvs all stocks (USD)
Total Current Assets
2.91BUSDFY2025 · Dec 31, 2025Total Liabilities
3.12BUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.67BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.61BUSDFY2025 · Dec 31, 2025Total Current Liabilities
517.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
529.80MUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.01BUSDFY2025 · Dec 31, 2025Accounts Receivable
460.60MUSDFY2025 · Dec 31, 2025Inventory
740.70MUSDFY2025 · Dec 31, 2025Accounts Payable
129.00MUSDFY2025 · Dec 31, 2025Short-term Debt
37.40MUSDFY2025 · Dec 31, 2025Other Current Liabilities
141.70MUSDFY2025 · Dec 31, 2025Long-term Debt
1.35BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
197.80MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
8.18BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
7.45BUSDvs all stocks (USD)
Treasury Stock
1.01BUSDFY2025 · Dec 31, 202552-Week Low
236.73USDUpdated Jul 18, 202652-Week High
343.12USDUpdated Jul 18, 202652-Week Change
24.61%vs all stocks
Beta
1.08xvs all stocks
50-Day MA
285.18USDUpdated Jul 18, 2026200-Day MA
294.48USDUpdated Jul 18, 2026Avg 10-Day Volume
236.44KSharesUpdated Jul 18, 2026Avg 30-Day Volume
308.80KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
6.00USDUpdated Jul 18, 2026Other Income / Expense
730.40MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: 0.07
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.04Revenue Growth YoY: 0.01
Financial Health
Altman Z-Score 3.49: safe zoneNotable
Altman Z-Score: 3.49
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $8.15B, above the global median of $1.15BNotable
Market cap (USD): 8,145,159,699Global Median: 1,146,734,693.424
Revenue is $2.59B, above the global median of $520.53MNotable
Revenue (USD): 2,589,900,032Global Median: 520,528,949.311
Levered free cash flow is $229.76M, above the global median of $16.24MNotable
Levered free cash flow (USD): 229,762,496Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Chien Kuo Construction Co., Ltd.
2 interpretationsFCF Ratios ElevatedCash-Flow Ratios Elevated
Shanghai Zhonggu Logistics Co., Ltd.
2 interpretationsFCF Ratios ElevatedCash-Flow Ratios Elevated
Agnico Eagle Mines Limited
2 interpretationsFCF Ratios ElevatedCash-Flow Ratios Elevated